Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 99

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Study on the Safety and Effectiveness of CSL889 for Adults and Adolescents with Sickle Cell Disease During Painful Crises

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hemopexin, human
  • Sponsor:CSL Behring LLC

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Long-term Safety of Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Endometrial cancer+4

Not recruiting

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Raludotatug Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:iOnctura SA

Study on ABBV-400, Fluorouracil, Leucovorin, and Budigalimab for Advanced or Metastatic Stomach and Esophageal Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ocular myasthenia

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Obesity

Not recruiting

Study on Maintaining Weight Loss in Teens with Obesity Using Semaglutide

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Acute kidney injury

Not recruiting

Study of GDC-8264 compared to placebo for preventing kidney injury in patients at risk of acute kidney injury after heart surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7288817
  • Sponsor:Genentech Inc.

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.